Search This Blog

Monday, February 4, 2019

Alexion Pharmaceuticals gains after Q4 beat

Alexion Pharmaceuticals (ALXN +2.7%Q4 results: Revenues: $1,128.8M (+24.1%); SOLIRIS: $976.7M (+23.3%); STRENSIQ: $126.1M (+31.9%); KANUMA: $25.7M (+17.4%).
Net Loss: ($45M); Non-GAAP Net Income: $486.4M (+44.1%); Loss Per Share: ($0.20); Non-GAAP EPS: $2.14 (+44.6%).
2019 Guidance: Revenues: $4,625M – $4,700M; SOLIRIS/ULTOMIRIS revenues: $3,970M – 4,020M; EPS: $6.14 – 7.26; Non-GAAP EPS: $9.10 – 9.30.
U.S. launch underway for ULTOMIRIS (ravulizumab-cwvz) in adults with paroxysmal nocturnal hemoglobinuria; EU and Japanese applications under review.
The Company has filed U.S. and EU submissions for SOLIRIS in neuromyelitis optica spectrum disorder and is on track to file in Japan later in 2019.
ALXN has also collaborated with Caelum Biosciences.
The consensus non-GAAP EPS and Revenue estimate were $1.82 and $1.06B, respectively.
Shares are up 3% premarket.

Alexion Pharmaceuticals, Inc. 2018 Q4 – Results – Earnings Call Slides

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings call.

CVS Health No Cost Heart Health Screenings Valentine’s Day for Women


As part of its ongoing commitment to building healthier communities, CVS Health (NYSE: CVS) today announced it will be offering no cost “Know Your Numbers” heart health screenings at MinuteClinic, the company’s retail medical clinic, every Thursday in February, including Valentine’s Day. MinuteClinic locations can be found inside select CVS Pharmacy and Target stores in 33 states and the District of Columbia.

The company also announced it has extended its support of the American Heart Association’s Go Red for Women campaign with a new three-year, $15 millioncommitment to life-saving cardiovascular research and education. CVS Pharmacy customers will have an opportunity to give the gift of heart health by making a donation at the register at their local CVS Pharmacy stores through February 23.
According to the American Heart Association, nearly 80 percent of cardiac events can be prevented, yet most women don’t know their personal health numbers that are critical to determining one’s risk.
“Women tend to put others before themselves, but it is imperative that women make their heart health a priority. The stark reality is cardiovascular diseases continue to be a woman’s greatest health threat, claiming the lives of 1 in 3 women. But by empowering women to be aware – which includes knowing your numbers – move more, eat smart and manage blood pressure, we can change that fact,” said Jennifer Mieres, M.D., an American Heart Association’s Go Red for Women medical expert.
Consumers can visit their local MinuteClinic on February 7, 14, 21, and 28 and receive a no-cost heart health preventive screening, supported by TYLENOL®, to learn the five key personal health numbers that can help them determine their risk for heart disease: total cholesterol, HDL (good) cholesterol, blood pressure, blood sugar and body mass index. MinuteClinic is a high-quality, convenient and affordable destination for preventive care all year long, with 1 in 2 Americans living within 10 miles of a MinuteClinic.
“Knowing your risk for cardiovascular disease and stroke is critical to improving community health, which is why we’re pleased to be offering no cost Know Your Number screenings at all of our MinuteClinic locations on Valentine’s Day, and every Thursday during February,” said Lisa Bisaccia, Chief Human Resources Officer, CVS Health, and national volunteer chair for Go Red for Women. “Health starts at the community level, and that’s why we feel we can make a real difference by increasing access to cardiovascular screenings and providing customers with an opportunity to show their support for family, friends and neighbors who are affected by cardiovascular disease.”
To receive a free screening, download the voucher, print a copy and bring it with you to scan at the MinuteClinic registration kiosk. Alternatively, you can use your mobile phone to show the voucher to the provider after you register at the kiosk.

Baird Upgrades Addus HomeCare (ADUS) to Outperform

Baird analyst Matthew Gillmor upgraded Addus HomeCare (NASDAQ: ADUS) from Neutral to Outperform with a price target of $75.00

Dr. Reddy’s upgraded to Buy from Neutral at CL King

https://thefly.com/landingPageNews.php?id=2858091

Nightstar Therapeutics shares can rally 60% on positive data, says Mizuho

Nightstar Therapeutics shares can rally 60% on positive data, says Mizuho. Mizuho analyst Yang says Nightstar Therapeutics is one of her firm’s top picks for 2019. The analyst sees an attractive valuation into the mid-2019 data from the Phase 2/3 expansion study in XLRP, which she calls the stock’s most important catalyst. If the data are positive, Yang sees “significant upside” of 60% to her $22 price target. Further, downside “appears limited” as the pathway to registration for the Nightstar’s most advanced pipeline program in choroideremia is “de-risked” given positive data and alignment with FDA draft guidance on clinical trial design, Yang tells investors in a research note. She reiterates a Buy rating on Nightstar Therapeutics.

Piper Jaffray likes the set-up for Cigna shares in 2019

Piper Jaffray analyst Sarah James likes the set-up for Cigna (CI) in 2019. The company has built 25c-50c of conservatism into its earnings guidance and has potential for a “strong” 2020 driven by better cost trend control, its specialty business, and working down the $200M stranded overhead cost from Anthem’s departure, James tells investors in a research note. Further, the analyst does not have the pharmacy benefits manager volume coming back in-house from UnitedHealth (UNH) in her numbers yet, which she sees as “likely upside to 2021.” The analyst also believes Cigna “screens as cheap” at 10.6 times expected 2020 earnings. James reiterates an Overweight rating on the shares with a $227 price target.